 CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq:RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced that the Company will present clinical results from its ongoing Phase 12 study of RTX-240 in advanced solid tumors during Week One of the American Association for Cancer Research AACR Virtual Annual Meeting being held from April 10-15, 2021. Posters will be available online on the first day of the conference on April 10 and will remain available for viewing through June 21, 2021. 